Dane County Drug Court Study for Addicted Offenders

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The proposed work addresses critical health and public safety issues in the U.S. and in Wisconsin: the intersection of addiction and crime and the prevention of associated individual and public health complications. The results will provide justification for the expanded involvement of primary care in the treatment of substance-related disorders (opioid dependence in particular) and the prevention of their complications. As such, the project answers to federal calls for the expansion of substance abuse treatment into primary care settings and to objectives within the Alcohol and Drug Focus Area of Healthiest Wisconsin 2020.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• Enrollment in the Drug Treatment Court

• diagnosis of opioid dependence using the Addiction Severity Index-Lite and diagnosis by clinical staff of referring units

• opioid positive urine drug screen at baseline

• women of childbearing potential who have a negative screening urine pregnancy test and are willing to use reliable birth control methods throughout the duration of the study.

Exclusion Criteria:

• pregnancy

• women who are currently breastfeeding

• complex psychiatric co-morbidity (e.g. suicidality, psychosis)

• complex medical co-morbidity (e.g. major cardiovascular, renal, or gastrointestinal/hepatic disease)

• or current pharmacotherapy with an agent which is contraindicated in combination with buprenorphine/naloxone according to drug labeling (

• Specific medical conditions, to be identified via initial medical history and examination, which would necessitate exclusion from study participation include: paralytic ileus, coronary artery disease or heart arrhythmia, recent head injury, obstructive sleep apnea, severe asthma or COPD, end-stage renal disease, or severe morbid obesity.